Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report)’s share price was up 5.2% on Tuesday . The company traded as high as $87.53 and last traded at $87.9450. Approximately 217,736 shares traded hands during mid-day trading, a decline of 76% from the average daily volume of 892,121 shares. The stock had previously closed at $83.60.
Analyst Upgrades and Downgrades
A number of research analysts recently weighed in on DNTH shares. William Blair reiterated an “outperform” rating on shares of Dianthus Therapeutics in a report on Monday, March 16th. Raymond James Financial upgraded Dianthus Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their target price for the company from $63.00 to $123.00 in a report on Tuesday, March 10th. Jefferies Financial Group set a $98.00 target price on Dianthus Therapeutics and gave the company a “buy” rating in a report on Monday, March 9th. Wall Street Zen upgraded Dianthus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Wedbush lifted their target price on Dianthus Therapeutics from $103.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, May 6th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $117.82.
Get Our Latest Stock Analysis on Dianthus Therapeutics
Dianthus Therapeutics Price Performance
Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.22. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%.The company had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.40 million. Equities research analysts expect that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current fiscal year.
Insider Buying and Selling
In other Dianthus Therapeutics news, EVP Ryan Savitz sold 114,367 shares of the firm’s stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $83.00, for a total value of $9,492,461.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Edward Carr sold 43,682 shares of Dianthus Therapeutics stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $81.49, for a total value of $3,559,646.18. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 323,021 shares of company stock valued at $26,564,008. 3.02% of the stock is owned by company insiders.
Institutional Trading of Dianthus Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Stempoint Capital LP increased its position in shares of Dianthus Therapeutics by 7.8% during the first quarter. Stempoint Capital LP now owns 85,502 shares of the company’s stock worth $7,175,000 after acquiring an additional 6,218 shares during the last quarter. Janus Henderson Group PLC increased its position in shares of Dianthus Therapeutics by 96.4% during the first quarter. Janus Henderson Group PLC now owns 16,500 shares of the company’s stock worth $1,384,000 after acquiring an additional 8,100 shares during the last quarter. ADAR1 Capital Management LLC purchased a new stake in shares of Dianthus Therapeutics during the first quarter worth about $4,616,000. California State Teachers Retirement System increased its position in shares of Dianthus Therapeutics by 155.5% during the first quarter. California State Teachers Retirement System now owns 40,584 shares of the company’s stock worth $3,406,000 after acquiring an additional 24,697 shares during the last quarter. Finally, Royal Bank of Canada increased its position in shares of Dianthus Therapeutics by 847.5% during the first quarter. Royal Bank of Canada now owns 19,064 shares of the company’s stock worth $1,601,000 after acquiring an additional 17,052 shares during the last quarter. 47.53% of the stock is owned by hedge funds and other institutional investors.
Dianthus Therapeutics Company Profile
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.
Featured Articles
- Five stocks we like better than Dianthus Therapeutics
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
